Navigation Links
GBM -Ab EIA Auto-Immune Markers 013-GBM-48 Glomerular Basement Membrane

ProductsGBM -Ab EIA Auto-Immune Markers 013-GBM-48 Glomerular Basement Membrane
Company ALPCO Diagnostics
Item GBM -Ab EIA Auto-Immune Markers 013-GBM-48 Glomerular Basement Membrane
Features 
Description This Immunoscan Anti-GBM was developed to detect the presence of antibodies against the glomerular basement membrane. The information is clinically useful in diagnosing Goodpastures syndrome, where anti-collagen (IV) - a3 chain antibody formation along with glomerulonephritis and pulmonary hemorrhage are primary diagnostic parameters. Since there are several other conditions presenting with similar symptoms, developed independently from anti-glomerular basement membrane (GBM) antibodies, this test can help to differentiate between these autoimmune renal disorders. The antigen used in the test is the M2 subunit purified from the noncollagenous (NC1) domain of type IV collagen. This antigen is fully described in the review article Biology of Disease Goodpasture Syndrome: Molecular Architecture and Function of Basement Membrane Antigen (1). Recent studies have shown that all Goodpasture patients have antibodies directed against M2 and some patients have additional antibodies against other basement membrane constituents and/or other collagen IV domains. The use of this purified antigen does not give false positive results for patient specimens containing other autoantibodies to the GBM, in contrast to crude collagenase digests of the total GBM (2). Glomerulonephritis is a major cause of irreversible renal failure. Many forms of glomerulonephritis are caused by immunological mechanisms, whereby a person forms antibodies against his own tissue components (auto-immunity) (3). Dixon and coworkers (4, 5) showed that in one particular type of glomerulonephritis, originally described by Ernest Goodpasture in 1919 (6) and subsequently referred to as Goodpastures syndrome (7), the disease was caused by an antibody response against antigens present in the glomerular basement membrane (GBM). Thus the disease is sometimes referred to as anti-GBM mediated glomerulonephritis. While Goodpastures syndrome is a relatively rare condition, the disease is rapidly progressive and, unless treated, has a case-fatality rate of 75-90% (8). Immediate and correct treatment is necessary before kidney (and often lung) damage has progressed too far. In clinical practice the diagnosis and recognition of the disease is frequently delayed since it is unexpected. Clinical signs such as hemoptysis, precipitate anemia, pulmonary opacities at x-ray and/or oliguria are in a sense unspecific and common to a variety of disorders. Mild prodromal lung or kidney symptoms are often overlooked or masked by a precipitating infection. The Immunoscan Anti-GBM offered is based on ELISA methodology (15, 16). The test utilizes wells coated with purified GBM antigen. Diluted patient serum is applied to the well and incubated. If specific anti-GBM antibodies are present they will bind to the antigen. Unbound material is washed away and any bound antibody is detected by adding enzyme-labeled anti-human IgG, followed by a second washing step and incubation with substrate. A well containing anti-GBM antibody will develop a color, which can be quantified.
Info ALPCO DiagnosticsCall ALPCO Diagnostics to buy products (US and Canada only; other locations use number below) USACanada1-866-466-7731

Customer Service: (800) 592-5726
Web site: http://www.alpco.com

Related medicine products :

1. CIC (C1-q) EIA Auto-Immune Markers 001-EK-CIC Circulating Immune Complexes
2. GBM -Ab EIA Auto-Immune Markers 013-GBM-96 Glomerular Basement Membrane
3. Anti-PR3 EIA Auto-Immune Markers 013-PR3-48 Proteinase
4. Anti-MPO ANCA EIA Auto-Immune Markers 013-MPO-96 Myeloperoxidase
5. Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase
6. Anti-MPO ANCA EIA Auto-Immune Markers 013-MPO-48 Myeloperoxidase
7. ENA Screen EIA Auto-Immune Markers 012-MDKES1 Extractable Nuclear Antigens
8. Surgical Markers
9. TLS Surgical Markers
10. SQUEEZE-MARK Surgical Markers
11. Iso-Insulin EIA Diabetes and Obesity Markers 008-10-1128-01
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medium....
Medicine Products:
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well has launched ... The drinks have been produced in collaboration with Zlatan Ibrahimovic and have been ... , After a successful launch in Sweden last year, the next generation sports ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a ... has set out for each of his children. “The Angel” is the creation of ... Music in New York City, and impassioned writer. , When asked of her new ...
(Date:1/20/2017)... ... , ... “I Forgive You”: a fine examination of how God handles sin, including how ... published author, Stephen Miller, who, for over ten long years has been waiting to release ... Trinidad and Tobago, he has been serving the Lord for over twenty years, and he ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “Christmas in Suffolk”: ... of published author, Sara Seymour, who lives in Lafayette, Indiana where she works in ... on iced coffees and writes. , Published by Christian Faith Publishing, Sara Seymour’s new ...
(Date:1/20/2017)... ... 2017 , ... “Knowledge is God’s Lighthouse”: a moving and colorful collection ... is the creation of published author, Gene Gaapf, a retired truck driver, and a ... have been writing since high school and have many different titles,” Gaapf mentions about ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... NEW YORK , Jan. 19, 2017 ... ... Forecast 2016-2026: Opportunities for Leading Companies – our new ... new report discusses issues and events affecting the Alzheimer,s ... qualitative analyses to answer these key questions: - How ...
(Date:1/19/2017)... , Jan. 19, 2017  Stealth BioTherapeutics Inc. ... to treat mitochondrial dysfunction, today announced new additions to ... M.D., as Chief Medical Officer, and Daniel Geffken ... announced that Jim Carr , Pharm.D. has been ... "We are pleased to welcome Doug and Daniel to ...
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
Breaking Medicine Technology: